< Back to previous page
Patent
Treatment of central nervous tumours
The present invention generally relates to a new formulation containing nanoparticles encapsulating siRNA for the use of RNAi technology for gene silencing of galectin-1 involved in tumour progression. More in particular the present invention relates to the use of RNAi molecules for treating central nervous cancer, more in particular for treating glioblastoma multiforme (GBM).
Patent Publication Number: US11007154
Year filing: 2021
Year approval: 2021
Year publication: 2021
Status: Assigned
URI: link to Espacenet
Technology domains: Pharmaceuticals
Validated for IOF-key: Yes
Attributed to: Associatie KULeuven